Ultragenyx is trading 6.4% up at $27.47 in pre-market sessions after reporting record second-quarter revenue and a narrower-than-expected net loss per share.
- The company beat consensus estimates on both revenue and EPS while reaffirming its 2026 revenue outlook of $730M–$760M.
- Management highlighted a clinical pipeline entering a transformative period, which is supporting sustained bullish sentiment toward the stock.